Stocks
Nektar TherapeuticsNKTR
NASDAQHealthcareBiotechnology$73.25+4.11%
A clinical-stage biotechnology company focused on developing immune-modulating therapies for autoimmune diseases, cancer, and other chronic conditions. Its pipeline includes biologic drug candidates designed to selectively regulate immune responses, with value largely tied to clinical trial outcomes...
Market Cap: $1.5B52W Range: $6.45 – $77.00
Congressional Interest in Nektar Therapeutics (NKTR)
2 members of Congress have disclosed 3 trades in Nektar Therapeutics (NKTR), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 2 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
2
Buys
1
Sells
2
Who in Congress Is Trading NKTR?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2019-12-30 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2018-06-21 | Josh Gottheimer | sell | $1K – $15K |